Hereditary angioedema or HAE in short, is a rare genetic disorder in which patients experience sudden onset of swelling in various locations of the body. There are two kinds of HAE treatments - preventive and on-demand. While preventive or prophylactic HAE treatment helps prevent or minimize the frequency and severity of HAE attacks, the on-demand HAE treatment is used to treat the symptoms of a HAE attack.
The company we are profiling today is KalVista Pharmaceuticals Inc. (KALV), which is developing a franchise of oral treatments for HAE - both on-demand and prophylactic HAE drugs.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com